Corcept Therapeutics (NASDAQ:CORT) Trading Up 6.8% on Analyst Upgrade

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock price was up 6.8% during mid-day trading on Friday after Canaccord Genuity Group raised their price target on the stock from $99.00 to $100.00. Canaccord Genuity Group currently has a buy rating on the stock. Corcept Therapeutics traded as high as $43.23 and last traded at $44.1280. Approximately 1,096,772 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 2,578,029 shares. The stock had previously closed at $41.30.

Several other brokerages also recently weighed in on CORT. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research report on Wednesday, December 31st. Wall Street Zen lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Truist Financial set a $50.00 price objective on shares of Corcept Therapeutics in a report on Wednesday, December 31st. Finally, UBS Group initiated coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price for the company. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $83.50.

Insider Buying and Selling at Corcept Therapeutics

In other news, CEO Joseph K. Belanoff sold 40,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,701,370 shares in the company, valued at approximately $215,488,284.90. The trade was a 1.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Guyer sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $35.18, for a total transaction of $703,600.00. Following the transaction, the insider owned 1,235 shares of the company’s stock, valued at approximately $43,447.30. This represents a 94.18% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 194,500 shares of company stock valued at $14,186,410. 20.80% of the stock is currently owned by company insiders.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

Institutional Trading of Corcept Therapeutics

Institutional investors have recently modified their holdings of the company. Pathstone Holdings LLC raised its holdings in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after purchasing an additional 144 shares during the last quarter. Huntington National Bank lifted its position in Corcept Therapeutics by 54.0% during the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after buying an additional 168 shares in the last quarter. Campbell Newman Asset Management Inc. boosted its stake in shares of Corcept Therapeutics by 0.5% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after buying an additional 170 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Corcept Therapeutics by 1.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock worth $730,000 after buying an additional 180 shares during the last quarter. Finally, Clearstead Advisors LLC boosted its position in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Stock Performance

The stock has a market capitalization of $4.63 billion, a P/E ratio of 49.98 and a beta of 0.23. The stock has a 50 day simple moving average of $65.24 and a two-hundred day simple moving average of $71.10. The company has a quick ratio of 3.07, a current ratio of 3.14 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The company had revenue of $207.64 million for the quarter, compared to the consensus estimate of $223.78 million. During the same quarter in the prior year, the company earned $0.41 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. On average, equities analysts forecast that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.